


# Supplementary Material: Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation

Akihiro Yoshimura, Tadaaki Yamada, Naoko Okura, Takayuki Takeda, Kazuki Hirose, Yutaka Kubota, Shinsuke Shiotsu, Osamu Hiranuma, Yusuke Chihara, Nobuyo Tamiya, Yoshiko Kaneko, Junji Uchino and Koichi Takayama



**Figure S1.** Patient flowchart of NSCLC with EGFR-T790M mutation after they acquired resistance to initial EGFR-TKIs. A total of 78 EGFR-mutant NSCLC patients underwent re-biopsy and 39 NSCLC patients was detected to have the EGFR-T790M mutation. Of these patients, 27 received osimertinib treatment with measurable lesions. In addition, they could continue receiving initial EGFR-TKIs after adverse events until disease progression.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).